Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMQB3HD)

• Drug Name: XmAb22841 Drug Info
• Synonyms: XmAb841

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 1	[1]

• Cross-matching ID: TTD Drug ID: DMQB3HD

Molecule-Related Drug Atlas

Drug(s) Targeting Cytotoxic T-lymphocyte protein 4 (CTLA-4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ipilimumab	DMJTIYK	Melanoma	2C30	Approved	[3]
Tremelimumab	DMOQ9H1	Hepatocellular carcinoma	2C12.02	Approved	[4]
KN046	DMSDBPG	Non-small-cell lung cancer	2C25.Y	Phase 3	[5]
AK04	DMU7K86	Actinic keratosis	EK90.0	Phase 3	[6]
AK104	DMXJ8Z4	Cervical cancer	2C77.0	Phase 2	[7]
Lorigerlimab	DM2E8Z5	Prostate cancer	2C82.0	Phase 2	[8]
Vudalimab	DMSEEI0	Prostate cancer	2C82.0	Phase 2	[9]
AGEN1884	DMAP5B4	Cervical cancer	2C77.0	Phase 1/2	[10]
BMS-986288	DMM10J4	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[11]
MK-1308	DM25QKC	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[12]

Drug(s) Targeting Lymphocyte activation gene 3 protein (LAG3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Relatlimab	DM28AZV	Melanoma	2C30	Approved	[13]
Anti-LAG3	DMJO402	Gastric adenocarcinoma	2B72	Phase 2	[10]
BMS-986016	DMDCHM7	Hematologic tumour	2B33.Y	Phase 1/2	[14]
IMP-321	DM18ZLW	Allergy	4A80-4A85	Phase 1/2	[15]
Favezelimab	DMYAIE2	Non-hodgkin lymphoma	2B33.5	Phase 1/2	[16]
FS118	DM0QH9K	Advanced cancer	2A00-2F9Z	Phase 1	[17]
RG6139	DMJFM3O	Solid tumour/cancer	2A00-2F9Z	Phase 1	[18]
ADPT01	DMS6DPF	Breast cancer	2C60-2C65	Phase 1	[19]
IMP-701	DMXSMF9	Solid tumour/cancer	2A00-2F9Z	Phase 1	[20]
GSK2831781	DMC47M9	Autoimmune disease	4A40-4A45	Phase 1	[21]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Cytotoxic T-lymphocyte protein 4 (CTLA-4)	TTI2S1D	CTLA4_HUMAN	Not Available	[2]
Lymphocyte activation gene 3 protein (LAG3)	TTNVXAW	LAG3_HUMAN	Not Available	[2]

References

• [1] ClinicalTrials.gov (NCT03849469) A Study of XmAb22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors (DUET-4). U.S. National Institutes of Health.
• [2] Clinical pipeline report, company report or official report of Xencor.
• [3] Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
• [4] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2743).
• [5] Clinical pipeline report, company report or official report of Alphamab Oncology.
• [6] A multicenter, open-label phase Ib/II study of cadonilimab (anti PD-1 and CTLA-4 bispecific antibody) monotherapy in previously treated advanced non-small-cell lung cancer (AK104-202 study). Lung Cancer. 2023 Oct;184:107355.
• [7] Clinical pipeline report, company report or official report of Akeso Biopharma.
• [8] Clinical pipeline report, company report or official report of MacroGenics
• [9] Clinical pipeline report, company report or official report of Xencor
• [10] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [11] Clinical pipeline report, company report or official report of CytomX Therapeutics.
• [12] Safety and efficacy of quavonlimab, a novel anti-CTLA-4 antibody (MK-1308), in combination with pembrolizumab in first-line advanced non-small-cell lung cancer. Ann Oncol. 2021 Mar;32(3):395-403.
• [13] FDA Approved Drug Products from FDA Official Website. 2022. Application Number: 761234
• [14] Nivolumab in NSCLC: latest evidence and clinical potential. Ther Adv Med Oncol. 2015 March; 7(2): 85-96.
• [15] A soluble form of lymphocyte activation gene-3 (IMP321) induces activation of a large range of human effector cytotoxic cells. J Immunol. 2007 Sep 15;179(6):4202-11.
• [16] A first-in-human study of the anti-LAG-3 antibody favezelimab plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer. ESMO Open. 2022 Dec;7(6):100639.
• [17] Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730.
• [18] Clinical pipeline report, company report or official report of Genentech.
• [19] Clinical pipeline report, company report or official report of Novartis.
• [20] IMP321 (sLAG-3), an immunopotentiator for T cell responses against a HBsAg antigen in healthy adults: a single blind randomised controlled phase I study. J Immune Based Ther Vaccines. 2007 Mar 29;5:5.
• [21] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)